Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study
Primary result · Change in IHLResult — go to the resultBetween-group difference −3.3 95% CI −6.5 to −0.1Authors' conclusion
Empagliflozin significantly improves hepatic steatosis compared with sitagliptin, and this may protect against subsequent hepatic insulin resistance. Early administration of SGLT2 inhibitors is preferable for T2D patients with NAFLD.
Study context
- Population
- Patients with T2D and non-alcoholic fatty liver disease (NAFLD); at baseline mean diabetes duration 3.7 years, HbA1c 7.2%, IHL 20.9%; median NAFLD activity score 3.0
- Participants
- 44 patients
- Comparison
- Empagliflozin vs sitagliptin
- Primary endpoint
- Change in intrahepatic lipid content (IHL) measured by proton magnetic resonance spectroscopy (1 H-MRS)
- Follow-up
- 12 weeks
Methodological detailsprospective
- Prospective
Primary result
Change in IHL
Between-group difference
−3.3
95% CI −6.5 to −0.1
P = 0.044
Change by group
Empagliflozin
−5.2%
± 1.1%
Sitagliptin
−1.9%
± 1.2%
Empagliflozinvs Sitagliptin
between-group difference −3.3 (95% CI −6.5 to −0.1); P = 0.044
As reported in the abstract
Secondary outcomes
Change in insulin sensitivity in liver, muscle or adipose tissue · 12 weeks
- No significant between-group differences in change of insulin sensitivity in liver, muscle or adipose tissue
Hepatic insulin sensitivity within groups · 12 weeks
- Hepatic insulin sensitivity significantly increased only with empagliflozin; significantly negatively associated with change in IHL
Original publication
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study. Diabetes Obes Metab. Published 21 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →